Indianapolis, IN, United States of America

Sajan Joseph

This inventor holds 26 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Compounds. Top assignee: Eli Lilly and Company. Active years: 2003-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sajan Joseph. Retrieved from https://idiyas.com/inventor/sajan-joseph

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 7)

% Patents Active = 26.9

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 5.8

ph-index = 7

Forward Citations = 185(Granted Patents)

Location History:

Indianapolis, IN (US) (2003 - 2011)
Bengaluru, IN (2012)
Carmel, IN (US) (2015 - 2021)

Company Filing History:

26 out of 4,517

Eli Lilly and Company

patents

Years Active: 2003-2021

Loading Chart...

Areas of Expertise:

ERK Inhibitors

AKT Inhibitors

P70 S6 Kinase

Thrombin Inhibitors

Antithrombotic Amides

Proliferative Diseases

Heterocyclic Carboxamides

Aromatic Amides

Aminopyridyloxypyrazole

Substituted Carboxamides

Isoquinoline Derivatives

Factor Xa Inhibitors

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE48635 - ERK inhibitors (2021-07-12),

2. 9879029 - ERK inhibitors (2018-01-30),

3. 9617243 - Aminopyridyloxypyrazole compounds (2017-04-11),

4. 9526733 - ERK inhibitors (2016-12-27),

5. 9469652 - ERK inhibitors (2016-10-18),

6. 9067920 - Compounds useful for inhibiting Chk1 (2015-06-30),

7. 8148387 - AKT and P70 S6 kinase inhibitors (2012-04-03),

8. 8093383 - P70 S6 kinase inhibitors (2012-01-10),

9. 7998977 - Inhibitors of AKT (protein kinase B) (2011-08-16),

10. 7700628 - Aromatic ether derivatives useful as thrombin inhibitors (2010-04-20),

11. 7449477 - 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) (2008-11-11),

12. 7449457 - Substituted heterocyclic carboxamides with antithrombotic activity (2008-11-11),

13. 7414063 - Inhibitors of Akt (protein kinase B) (2008-08-19),

14. 7163938 - Substituted carboxamides (2007-01-16),

15. 7160878 - Substituted heterocyclic amides (2007-01-09),

Title: Unveiling the Innovative Mind of Inventor Sajan Joseph

Introduction:

Inventor Sajan Joseph, based in Indianapolis, IN, is a visionary mind with a remarkable portfolio of 26 patents. His groundbreaking work in developing ERK inhibitors showcases his dedication to advancing the field of cancer treatment. Let's delve deeper into his journey of innovation and success.

Latest Patents:

Sajan Joseph's recent patents revolve around ERK inhibitors, thieno[2,3-c]pyrrol-4-one compounds that effectively inhibit the activity of extracellular-signal-regulated kinase (ERK). These compounds hold significant promise in the treatment of cancer, offering new avenues for therapeutic interventions in oncology.

Career Highlights:

Currently affiliated with Eli Lilly and Company, Sajan Joseph has been instrumental in driving forward cutting-edge research and development within the pharmaceutical industry. His expertise and passion for innovation have led to the creation of impactful solutions with the potential to transform patient care.

Collaborations:

Throughout his career, Sajan Joseph has collaborated closely with esteemed professionals in the field, including his coworkers David Kent Herron and John Joseph Masters. This spirit of collaboration and partnership has enriched the depth and breadth of his innovative pursuits, fostering a culture of creativity and knowledge sharing.

Conclusion:

In conclusion, Sajan Joseph's inventive spirit and dedication to advancing cancer treatment through ERK inhibitors exemplify the essence of innovation in the medical field. His impactful contributions stand as a testament to the power of visionary thinking and collaborative effort in driving positive change. Sajan Joseph's legacy as an inventor continues to inspire and shape the future landscape of pharmaceutical research and development.

Profile summary based on public USPTO records.